Skip to main content
. Author manuscript; available in PMC: 2025 Feb 1.
Published in final edited form as: Schizophr Res. 2023 Dec 21;264:140–146. doi: 10.1016/j.schres.2023.12.022

Table 3:

Predictors of any engagement with psychiatric follow-up 12 months after discharge

Any MD visit
Any therapist visit
OR p-value 95% CI OR p-value 95% CI
Any relapse 12 months before ending CSC 0.82 0.66 0.34 1.98 1.14 0.786 0.43 3.02
Months in CSC 1.04 0.04 1.002 1.08 1.05 0.04 1.003 1.09
Non-white race 0.64 0.31 0.27 1.53 2.23 0.11 0.85 5.85
Male sex 0.76 0.60 0.28 2.11 0.42 0.12 0.14 1.24
Non-English speaking 0.66 0.56 0.16 2.72 0.36 0.23 0.067 1.91
#months with antipsychotic fill 1.064 0.32 0.94 1.2 1.04 0.58 0.91 1.18
Age at discharge 1.012 0.83 0.91 1.13 0.93 0.25 0.82 1.05
Cannabis use at last CSC contact 0.32 0.03 0.12 .90 0.53 0.26 0.17 1.6
Schizophrenia diagnosis 0.62 0.37 0.21 1.77 0.52 0.26 0.17 1.64
Alcohol use at exit 1.14 0.86 0.27 4.85 0.62 0.59 0.11 3.54
Insurance
Medicaid 0.54 0.21 0.21 1.40 0.44 0.16 0.14 1.37
Medicare 0.75 0.82 0.064 8.89 4.93 0.18 0.48 50.30
Private Insurance (comparator) 1 . . . 1 . . .
No insurance * . . . 0.97 0.98 0.09 10.68
*

Predicted failure perfectly due to small n (n=6), could not interpret HR